REAL STORIES. REAL WORKERS. REAL STRENGTH.
Latest Stories
Pfizer and Innovent Biologics have entered a global licensing and collaboration agreement valued at up to $10.5bn for the research and development of 12 early-stage cancer medicines. This significant deal highlights the ongoing innovation and investment in the pharmaceutical industry, potentially impacting American competitiveness and advancements in cancer treatment.
Eli Lilly’s $1.9 billion deal with Ascidian targets new kidney disease therapies, supporting U.S. biotech R&D and skilled jobs with potential benefits to communities and healthcare outcomes.
Hikma Pharmaceuticals plans to invest $267 million in Ohio manufacturing, boosting the local economy and potentially creating job opportunities. Meanwhile, Cingulate Therapeutics encounters challenges with the approval of their ADHD drug, highlighting the complexities of the pharma industry.
Eli Lilly’s recent $1.9 billion partnership with Ascidian underscores the pharma giant’s commitment to genetic medicines. This deal is part of a series of strategic moves aimed at advancing innovation in the pharmaceutical industry, potentially impacting American healthcare and the biotech sector.
A new proposal aims to include biotechnology in the COINS Act in response to recent acquisitions by Pfizer and Bristol Myers involving Chinese companies. The move reflects growing concerns about China’s advancements in drug manufacturing and their potential impact on national security, offering valuable insights for American industry and national competitiveness.
Eli Lilly and Company has forged a significant licensing agreement with Hanmi Pharm, valued at up to $1.26 billion, to collaborate on the development, manufacturing, and commercialization of Hanmi’s biologic drug candidate, sonefpeglutide, on a global scale excluding Korea. This partnership highlights the ongoing advancements in the pharmaceutical industry and underscores the importance of international collaborations in driving innovation and growth.
David Chang is set to depart from his role at the cell therapy maker Allogene after an eight-year tenure. In other developments, a next-generation blood disease drug faced setbacks, while an acquisition by AbbVie led to an FDA approval. These updates provide valuable insights into the pharmaceutical industry landscape and its impact on American healthcare and innovation.
AstraZeneca and Daiichi Sankyo have received approval from the US FDA for their drug Datroway (datopotamab deruxtecan) to address metastatic TNBC. This development could potentially impact American industry and healthcare by providing a new treatment option for patients with triple-negative breast cancer.
Eli Lilly, with plans to invest over $50 billion in U.S. manufacturing, will allocate an additional $4.5 billion to enhance two out of three new production sites in Lebanon, Indiana. This investment underscores the company’s commitment to strengthening its American manufacturing presence and contributes to local production, potentially benefiting workers and boosting industrial growth.
News on U.S. pharmaceutical manufacturing, biotech, drug production, medical supply chains, facilities, investment, and the workers supporting American health innovation.
Top Stories
